Abstract: The invention provides methods of treating and preventing vascular diseases, by inhibiting cysteine proteases active at sites of vascular injury, particularly cathepsins K and S, by administering cystatin C or TGF-&bgr;1. Cystatin C is severely reduced in both atherosclerotic and aneurysmal aortic lesions. Also provided is a method of diagnosing a patient at risk of, or with, vascular injury by detecting low levels of circulating cystatin C.
Type:
Grant
Filed:
October 26, 2000
Date of Patent:
August 10, 2004
Assignee:
The Brigham and Women's Hospital, Inc.
Inventors:
Harold A. Chapman, Guo-Ping Shi, Peter Libby, Galina K. Sukhova, Daniel I. Simon
Abstract: Disclosed are methods of identifying psychotropic agents that do not induce motor side effects using differential gene expression. Also disclosed are novel nucleic acid sequences whose expression is differentially regulated by psychotropic agents.
Abstract: Methods and kits for detecting polymorphisms that are predictive of a subject's susceptibility to developing an obstructive airway disease, such as asthma, as well as for determining the relative severity of the disease are described. Assays for identify therapeutics are also described.
Type:
Grant
Filed:
June 1, 2000
Date of Patent:
June 8, 2004
Assignee:
Interleukin Genetics, Inc.
Inventors:
Gordon W. Duff, Francesco S. di Giovine, Peter J. Barnes, Samson Lim
Abstract: Methods, assays and kits are disclosed for detecting a mother's or a fetus's susceptibility to an adverse pregnancy outcome such as low birth weight. The methods comprise obtaining a biological sample from a patient and determining the presence or absence of an IL-1 allele 2 of a marker that is associated with an adverse pregnancy outcome.
Type:
Grant
Filed:
October 20, 2000
Date of Patent:
May 11, 2004
Assignees:
Interleukin Genetics, Inc., The University of North Carolina at Chapel Hill
Inventors:
Kenneth S. Kornman, Gordon W. Duff, Steven Offenbacher
Abstract: Methods and kits for determining whether a subject has or is predisposed to developing a disease which is associated with IL-1 polymorphisms and assays for identifying therapeutics for treating and/or preventing the development of these diseases are provided.
Type:
Grant
Filed:
April 27, 2001
Date of Patent:
March 16, 2004
Assignee:
Interleukin Genetics, Inc.
Inventors:
Gordon W. Duff, Angela Cox, Nicola Jane Camp, Francesco S. di Giovine
Abstract: The invention provides nucleic acids containing single-nucleotide polymorphisms identified for transcribed human sequences, as well as methods of using the nucleic acids.
Abstract: The present invention provides novel isolated Wnt-7B-like polynucleotides and the membrane-associated or secreted polypeptides encoded by the Wnt-7B-like polynucleotides. Also provided are the antibodies that immunospecifically bind to a Wnt-7B-like polypeptide or any derivative, variant, mutant or fragment of the Wnt-7B-like polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the Wnt-7B-like polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
Type:
Grant
Filed:
July 26, 2000
Date of Patent:
November 25, 2003
Assignee:
CuraGen Corporation
Inventors:
Corine Vernet, Luca Rastelli, John Herrmann
Abstract: Interleukin-18 binding proteins which are capable of binding IL-18 and/or modulating and/or blocking IL-18 activity are provided. Methods for their isolation and recombinant production, DNAs encoding them, DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided.
Type:
Grant
Filed:
October 12, 2000
Date of Patent:
August 12, 2003
Assignee:
Yeda Research and Development Company Limited
Inventors:
Daniela Novick, Charles Dinarello, Menachem Rubinstein, Soo Hyun Kim
Abstract: The present invention relates to complexes of the HPS protein with proteins identified as interacting with HPS protein by a modified yeast two hybrid assay system. The proteins identified to interact with HPS protein are 14-3-3 protein, Hrs, atrophin-1, DGS-I, nuclear factor NF90, HPIP1 and human HN1 homolog protein. Accordingly, the present invention discloses complexes of HPS protein and 14-3-3 protein, Hrs, atrophin-1, DGS-I, nuclear factor NF90, HPIP1 and human HN1 homolog protein, and derivatives, fragments and analogs thereof. Additionally, the present invention also discloses nucleic acids encoding the HPIP1 and human HN1 homolog protein, or derivatives, fragments and analogs thereof. Methods of screening the complexes or proteins for efficacy in treating and/or preventing certain diseases and disorders, particularly atopic diseases, autoimmune diseases, neurodegenerative disease, cancer, pigmentation disorders, platelet dysfunction and viral diseases, are also disclosed herein.
Abstract: This invention relates to methods and formulations for the separation of biological macromolecules according to their size using capillary electrophoresis with improved polyacrylamide matrixes under denaturing conditions.
Type:
Grant
Filed:
August 13, 1999
Date of Patent:
April 29, 2003
Assignee:
CuraGen Corporation
Inventors:
Marie C. Ruiz-Martinez, Jan Berka, John W. Simpson
Abstract: The present invention describes polynucleotides and polypeptides associated with PPAR&agr;-mediated pathways that are useful as therapeutic compositions in method for the treatment of peroxisomal disorders. These polynucleotides and polypeptides were identified through the use of differentioal gene expression analysis. In particular, the present invention discloses eleven novel gene fragments, and numerous single nucleotide polymorphisms, located in previously disclosed genes, all of which have been discovered to be associated with PPAR&agr;-mediated pathways.
Abstract: Disclosed are nucleic acids encoding aortic carboxypeptidase-related polypeptides, polypeptides encoded by these nucleic acids, and methods of using these nucleic acids and polypeptides.